The Priority Review

Regulation Brief

FDA determines PEPCID RPD famotidine tablets not withdrawn for safety or effectiveness

The agency decided that the 20 mg and 40 mg orally disintegrating tablets were not removed from sale. This determination will allow FDA to approve abbreviated new drug applications for these products if all other legal and regulatory requirements are met.

Primary source

Federal Register notice, October 27, 2026

Determination That PEPCID RPD (Famotidine) Orally Disintegrating Tablets, 20 Milligrams and 40 Milligrams Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

Read the source: Determination That PEPCID RPD (Famotidine) Orally Disintegrating Tablets, 20 Milligrams and 40 Milligrams Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness federalregister.gov

Machine-summarized from the source above; not independently reported. How we use automation